Nutan Bhaskar, MD
Pulmonary Disease · Glendora
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 2
- Since medical school
- 23 years
- Graduated 2003
Offices
2 locations · California Pulmonary Associates Inc · 7 clinicians in this group
Hospitals listed: Chino Valley Medical Center · Emanate Health Foothill Presbyterian Hospital · Emanate Health Inter-Community Hospital · San Antonio Regional Hospital · San Dimas Community Hospital. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Bhaskar’s office at (626) 914-5219 to ask if they take your plan before you enroll.
Hospitals they work in
5 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Chino Valley Medical CenterChino, CAAcute Care Hospital · Proprietary · Has an emergency departmentPart of Prime Healthcare Services, which runs 45 hospitals in 14 statesPatients rate it 2 of 5 · 61% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.258, Oct 2024 – Sep 2025
- Emanate Health Foothill Presbyterian HospitalGlendora, CAAcute Care Hospital · Voluntary non-profit - Private · No emergency departmentPart of Emanate Health, which runs 3 hospitalsPatients rate it 2 of 5 · 63% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0, Oct 2024 – Sep 2025
- Emanate Health Inter-Community HospitalCovina, CAAcute Care Hospital · Proprietary · Has an emergency department · Birthing-friendlyPart of Emanate Health, which runs 3 hospitalsPatients rate it 2 of 5 · 60% would definitely recommend itOverall rating: 1 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0, Oct 2024 – Sep 2025
- San Antonio Regional HospitalUpland, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of San Antonio Regional HospitalPatients rate it 3 of 5 · 69% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.375, Oct 2024 – Sep 2025
- San Dimas Community HospitalSan Dimas, CAAcute Care Hospital · Proprietary · Has an emergency departmentPart of Prime Healthcare Services, which runs 45 hospitals in 14 statesPatients rate it 2 of 5 · 56% would definitely recommend itOverall rating: 2 of 5 starsNo measure marked better or worse than the national rate
See every measure and the patient survey for Chino Valley Medical Center
Behind the star rating — Deaths: 1 better, 2 the same, 0 worse of 3 measures. Safety: 1 better, 2 the same, 0 worse of 3 measures. Readmissions: 0 better, 3 the same, 0 worse of 3 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.258 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.02 (0 to 2.1) · 201 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.88 (0.44 to 1.31) | No different | Jul 2022 – Jun 2024 |
| Death rate for heart failure patientsComplications and deaths | 9.1 · 62 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14 · 165 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 14.6 · 38 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.7 · 966 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.19 (0 to 0.42) · 1,420 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.26 (0.05 to 0.47) · 1,449 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.27 (0.72 to 5.83) · 106 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.29 (0.57 to 4) · 93 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.74 (0.22 to 3.26) · 31 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.31 (0 to 1.27) · 921 cases | No different | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.6 · 40 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.7 · 167 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -9.3 · 71 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 53.4 · 160 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.7 · 296 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.2 · 43 cases | None | Jul 2023 – Jun 2025 |
What patients said (428 patients answered, 27% of those asked)
| Cleanliness | 4 |
| Nurse communication | 2 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 2 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 2 |
| Room was "always" clean | 77% |
| Nurses "always" communicated well | 69% |
| Doctors "always" communicated well | 70% |
| Staff "always" explained | 53% |
| Yes, staff "did" give patients this information | 80% |
| Yes, staff "did" give patients information about help after discharge | 75% |
| Doctors "always" explained things so they could understand | 67% |
| Doctors "always" listened carefully | 67% |
| Doctors "always" treated them with courtesy and respect | 76% |
| Patients who gave a rating of "9" or "10" (high) | 58% |
| Staff "always" explained new medications | 64% |
| Nurses "always" explained things so they could understand | 65% |
| Nurses "always" listened carefully | 65% |
| Nurses "always" treated them with courtesy and respect | 77% |
| "Always" quiet at night | 46% |
| "YES", patients would definitely recommend the hospital | 61% |
| Staff "always" explained possible side effects | 42% |
| Yes, staff "did" give patients information about possible symptoms | 85% |
See every measure and the patient survey for Emanate Health Foothill Presbyterian Hospital
Behind the star rating — Deaths: 0 better, 6 the same, 0 worse of 6 measures. Safety: 2 better, 4 the same, 0 worse of 6 measures. Readmissions: 1 better, 5 the same, 0 worse of 6 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.96 (0 to 2) · 475 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.16 (0.74 to 1.58) | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 9.2 · 45 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.3 · 43 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10.8 · 108 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.4 · 295 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 12.7 · 64 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 4.7 · 1,404 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.19 (0 to 0.41) · 2,439 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.3 (0.09 to 0.51) · 2,452 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.57 (1.08 to 6.06) · 286 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.65 (0 to 3.37) · 71 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.51 (0.83 to 4.19) · 283 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 10.99 (1.35 to 20.62) · 77 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.86 (1.63 to 10.08) · 56 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.71 (0.2 to 3.22) · 105 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.97 (0.06 to 1.88) · 1,999 cases | No different | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.662 | No different | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 1.026 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.5 · 44 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22 · 234 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 25.2 · 139 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -8 · 308 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 15.1 · 520 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.4 · 85 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.1 (9 to 16.2) · 293 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.6 to 1.2) · 174 cases | No different | Jan 2024 – Dec 2024 |
What patients said (582 patients answered, 16% of those asked)
| Cleanliness | 3 |
| Nurse communication | 2 |
| Doctor communication | 2 |
| Communication about medicines | 1 |
| Discharge information | 3 |
| Overall hospital rating | 2 |
| Quietness | 1 |
| Recommend hospital | 3 |
| Room was "always" clean | 64% |
| Nurses "always" communicated well | 73% |
| Doctors "always" communicated well | 73% |
| Staff "always" explained | 52% |
| Yes, staff "did" give patients this information | 83% |
| Yes, staff "did" give patients information about help after discharge | 80% |
| Doctors "always" explained things so they could understand | 69% |
| Doctors "always" listened carefully | 71% |
| Doctors "always" treated them with courtesy and respect | 78% |
| Patients who gave a rating of "9" or "10" (high) | 62% |
| Staff "always" explained new medications | 65% |
| Nurses "always" explained things so they could understand | 70% |
| Nurses "always" listened carefully | 68% |
| Nurses "always" treated them with courtesy and respect | 81% |
| "Always" quiet at night | 37% |
| "YES", patients would definitely recommend the hospital | 63% |
| Staff "always" explained possible side effects | 39% |
| Yes, staff "did" give patients information about possible symptoms | 87% |
See every measure and the patient survey for Emanate Health Inter-Community Hospital
Behind the star rating — Deaths: 0 better, 6 the same, 2 worse of 8 measures. Safety: 3 better, 4 the same, 0 worse of 7 measures. Readmissions: 0 better, 7 the same, 2 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.4 (0.39 to 2.4) · 990 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.85 (0.53 to 1.18) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 198.56 (145.92 to 251.21) · 69 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 3.9 · 48 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.9 · 99 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 13.8 · 107 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10.1 · 279 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 17.2 · 665 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 14.3 · 389 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 5.1 · 3,599 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.36) · 6,844 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.23 (0.03 to 0.42) · 6,958 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.21 (0.98 to 5.43) · 1,118 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.46 (0 to 3.08) · 379 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.05 (0.53 to 3.58) · 1,140 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.68 (1.69 to 15.67) · 450 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.07 (1.14 to 9) · 397 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.68 (0.18 to 3.17) · 216 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.32 (0 to 0.97) · 5,698 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.7 · 213 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.578 | No different | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.853 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.438 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.205 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.1 · 352 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.7 · 631 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -2 · 136 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 1.5 · 336 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -2.2 · 731 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.8 · 1,007 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.4 (3.5 to 8) · 53 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.2 (8.8 to 16.5) · 53 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.4 · 191 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 12.7 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.1 · 188 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.1 (9.6 to 17.6) · 113 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.1 (0.8 to 1.5) · 106 cases | No different | Jan 2024 – Dec 2024 |
What patients said (924 patients answered, 12% of those asked)
| Cleanliness | 3 |
| Nurse communication | 2 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 2 |
| Overall hospital rating | 2 |
| Quietness | 2 |
| Recommend hospital | 2 |
| Room was "always" clean | 64% |
| Nurses "always" communicated well | 70% |
| Doctors "always" communicated well | 70% |
| Staff "always" explained | 55% |
| Yes, staff "did" give patients this information | 81% |
| Yes, staff "did" give patients information about help after discharge | 77% |
| Doctors "always" explained things so they could understand | 64% |
| Doctors "always" listened carefully | 69% |
| Doctors "always" treated them with courtesy and respect | 77% |
| Patients who gave a rating of "9" or "10" (high) | 59% |
| Staff "always" explained new medications | 70% |
| Nurses "always" explained things so they could understand | 66% |
| Nurses "always" listened carefully | 67% |
| Nurses "always" treated them with courtesy and respect | 78% |
| "Always" quiet at night | 39% |
| "YES", patients would definitely recommend the hospital | 60% |
| Staff "always" explained possible side effects | 40% |
| Yes, staff "did" give patients information about possible symptoms | 85% |
See every measure and the patient survey for San Antonio Regional Hospital
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 3 better, 4 the same, 0 worse of 7 measures. Readmissions: 0 better, 6 the same, 2 worse of 8 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.375 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.42 (0.49 to 2.35) · 1,107 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.12 (0.8 to 1.44) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 167.04 (110.22 to 223.86) · 62 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.3 · 48 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 9.4 · 85 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.9 · 172 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 305 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.7 · 499 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 16.7 · 398 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 5 · 3,795 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.36) · 5,607 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.23 (0.03 to 0.43) · 5,828 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.55 (3.37 to 7.73) · 1,096 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.31 (0 to 2.85) · 315 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.77 (1.27 to 4.28) · 1,084 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 15.26 (8.83 to 21.68) · 347 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.6 (0.86 to 8.34) · 309 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.6 (0.14 to 3.05) · 331 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.35 (0 to 1.03) · 4,715 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.2 · 37 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.9 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.73 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.993 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.873 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.1 · 405 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.2 · 820 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 0.2 · 177 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 11 · 349 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 27.5 · 536 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18 · 970 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.9 · 35 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.2 · 106 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.4 · 179 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12 (9 to 16.1) · 285 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.3) · 234 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,938 patients answered, 16% of those asked)
| Cleanliness | 3 |
| Nurse communication | 2 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 66% |
| Nurses "always" communicated well | 72% |
| Doctors "always" communicated well | 71% |
| Staff "always" explained | 51% |
| Yes, staff "did" give patients this information | 83% |
| Yes, staff "did" give patients information about help after discharge | 80% |
| Doctors "always" explained things so they could understand | 66% |
| Doctors "always" listened carefully | 69% |
| Doctors "always" treated them with courtesy and respect | 78% |
| Patients who gave a rating of "9" or "10" (high) | 64% |
| Staff "always" explained new medications | 67% |
| Nurses "always" explained things so they could understand | 68% |
| Nurses "always" listened carefully | 69% |
| Nurses "always" treated them with courtesy and respect | 79% |
| "Always" quiet at night | 48% |
| "YES", patients would definitely recommend the hospital | 69% |
| Staff "always" explained possible side effects | 36% |
| Yes, staff "did" give patients information about possible symptoms | 87% |
See every measure and the patient survey for San Dimas Community Hospital
Behind the star rating — Deaths: 0 better, 3 the same, 0 worse of 3 measures. Safety: 0 better, 5 the same, 0 worse of 5 measures. Readmissions: 0 better, 3 the same, 2 worse of 5 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.03 (0 to 2.11) · 183 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.87 (0.44 to 1.29) | No different | Jul 2022 – Jun 2024 |
| Death rate for heart failure patientsComplications and deaths | 9.7 · 30 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 16.7 · 176 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.3 · 52 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.8 · 967 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.19 (0 to 0.41) · 1,478 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.25 (0.04 to 0.47) · 1,480 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.29 (0.72 to 5.85) · 115 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.67 (0 to 3.4) · 40 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.29 (0.57 to 4) · 123 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.15 (0 to 19.2) · 41 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.19 (0.87 to 9.52) · 41 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.75 (0.22 to 3.27) · 33 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.27 (0 to 1.15) · 1,132 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.2 · 103 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | No different | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 1.097 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.4 · 85 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 17 · 41 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 40.6 · 186 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.3 · 377 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.5 · 99 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20 · 44 cases | None | Jul 2023 – Jun 2025 |
What patients said (418 patients answered, 27% of those asked)
| Cleanliness | 4 |
| Nurse communication | 2 |
| Doctor communication | 1 |
| Communication about medicines | 2 |
| Discharge information | 1 |
| Overall hospital rating | 2 |
| Quietness | 1 |
| Recommend hospital | 2 |
| Room was "always" clean | 74% |
| Nurses "always" communicated well | 67% |
| Doctors "always" communicated well | 64% |
| Staff "always" explained | 51% |
| Yes, staff "did" give patients this information | 76% |
| Yes, staff "did" give patients information about help after discharge | 69% |
| Doctors "always" explained things so they could understand | 58% |
| Doctors "always" listened carefully | 63% |
| Doctors "always" treated them with courtesy and respect | 72% |
| Patients who gave a rating of "9" or "10" (high) | 50% |
| Staff "always" explained new medications | 69% |
| Nurses "always" explained things so they could understand | 63% |
| Nurses "always" listened carefully | 62% |
| Nurses "always" treated them with courtesy and respect | 76% |
| "Always" quiet at night | 36% |
| "YES", patients would definitely recommend the hospital | 56% |
| Staff "always" explained possible side effects | 32% |
| Yes, staff "did" give patients information about possible symptoms | 82% |
Original Medicare doctor bills
$456,371
Medicare paid this office $456,371 for 860 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 559 | $158,679 | $96 |
| Critical care, first 30-74 minutes | 279 | $152,784 | $170 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 386 | $65,711 | $64 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 237 | $35,415 | $139 |
| Subsequent nursing facility care with straightforward level of medical decision making, per day 20 minutes or more | 67 | $14,224 | $62 |
See all 17 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 559 | $158,679 | $96 |
| Critical care, first 30-74 minutes | 279 | $152,784 | $170 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 386 | $65,711 | $64 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 237 | $35,415 | $139 |
| Subsequent nursing facility care with straightforward level of medical decision making, per day 20 minutes or more | 67 | $14,224 | $62 |
| Return visit (30+ min) | 39 | $5,534 | $109 |
| Subsequent nursing facility care with moderate level of medical decision making, per day at least 30 minutes | 20 | $3,533 | $91 |
| New patient visit (45+ min) | 21 | $2,675 | $127 |
| Test to examine how well the lungs exchange gases | 35 | $2,057 | $49 |
| Test to determine lung volumes using sensors | 35 | $2,017 | $48 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 35 | $1,399 | $33 |
| Evaluation of use of breathing device | 43 | $988 | $15 |
| Test to measure expiratory airflow and volume initiated by patient and evaluated by provider | 34 | $781 | $19 |
| Comprehensive assessment of and care planning for patients requiring chronic care management services (list separately in addition to primary monthly care management service) | 13 | $775 | $52 |
| Test for exercise-induced lung stress | 27 | $767 | $27 |
| Test to measure largest amount of air breathed in an out | 33 | $521 | $13 |
| Hemoglobin measurement | 35 | $207 | $5 |
Procedures year by year
| Procedure | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Irrigation and suction of lung airways to obtain cells using an endoscope | 46 | 51 | 32 | 17 | 16 | – |
| Exam of lung airways using an endoscope | 39 | 42 | 25 | – | – | – |
| Aspiration of initial secretion of lung airway using an endoscope | – | – | – | – | 15 | – |
Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.
Who their Medicare patients are
860 Original Medicare patients in 2024. Average age 74 · Under 65 16% · 85 and older 21% · Women 51% · Also on Medicaid 68% · Health risk score 3.92. Sicker patients than 9 in 10 peers; the typical pulmonary disease clinician is at 2.13.
Conditions among them: High blood pressure 75% · Diabetes 65% · Heart failure 62% · Chronic kidney disease 60% · Coronary heart disease 53% · COPD 51% · Atrial fibrillation 45% · Depression 40% · Dementia 35% · Stroke 32% · Cancer 16%.
The office billed $943,867, Medicare allowed $577,442 and paid $456,371; for 4,620 services of 40 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 860 | 4,620 | 74 | 3.92 | $943,867 | $456,371 |
| 2023 | 843 | 8,841 | 75 | 2.78 | $1,165,358 | $436,431 |
| 2022 | 743 | 18,713 | 75 | 1.74 | $1,938,030 | $579,646 |
| 2021 | 779 | 19,595 | 74 | 1.61 | $2,122,835 | $610,855 |
| 2020 | 833 | 22,972 | 73 | 1.76 | $2,243,816 | $628,411 |
| 2019 | 998 | 27,848 | 73 | 1.77 | $2,567,284 | $708,278 |
| 2018 | 978 | 26,402 | 73 | 1.82 | $2,668,500 | $703,788 |
| 2017 | 1,036 | 22,960 | 72 | 2.23 | $2,948,413 | $765,676 |
| 2016 | 891 | 13,542 | 72 | 2.33 | $2,055,039 | $512,454 |
| 2015 | 518 | 2,910 | 72 | 2.48 | $544,911 | $161,061 |
| 2014 | 336 | 1,573 | 71 | 2.19 | $371,293 | $114,882 |
| 2013 | 143 | 676 | 68 | 1.75 | $211,792 | $52,885 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 24 services
| Critical care, first 30-74 minutes | 211 | $116,920 | $171 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 247 | $67,508 | $98 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 228 | $44,980 | $65 |
| Return visit (30+ min) | 290 | $23,690 | $78 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 139 | $20,970 | $143 |
| Test to examine how well the lungs exchange gases | 225 | $7,408 | $33 |
| Test to determine lung volumes using gas dilution or washout | 219 | $5,592 | $25 |
| Test to measure expiratory airflow and volume | 245 | $3,942 | $16 |
| New patient visit (45+ min) | 16 | $2,288 | $143 |
| New patient visit (60+ min) | 13 | $2,042 | $157 |
| Aspiration of initial secretion of lung airway using an endoscope | 13 | $1,789 | $119 |
| Irrigation and suction of lung airways to obtain cells using an endoscope | 15 | $1,122 | $70 |
| Ct scan of chest without contrast | 30 | $1,099 | $37 |
| Test to determine lung volumes using sensors | 15 | $745 | $50 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 15 | $527 | $35 |
| Evaluation of use of breathing device | 21 | $462 | $16 |
| Smoking and tobacco use intensive counseling, more than 10 minutes | 13 | $415 | $28 |
| Test for exercise-induced lung stress | 13 | $376 | $29 |
| Test to measure expiratory airflow and volume initiated by patient and evaluated by provider | 15 | $307 | $20 |
| X-ray of chest, 2 views | 19 | $300 | $15 |
| Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | 13 | $255 | $20 |
| Test to measure largest amount of air breathed in an out | 15 | $201 | $13 |
| Insertion of needle into vein for collection of blood sample | 11 | $67 | $6 |
| Hemoglobin measurement | 13 | $64 | $5 |
2022: 26 services
| Return visit (30+ min) | 463 | $69,004 | $89 |
| Critical care, first 30-74 minutes | 104 | $42,476 | $157 |
| Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | 183 | $23,062 | $38 |
| Test to examine how well the lungs exchange gases | 426 | $21,344 | $37 |
| Test to determine lung volumes using gas dilution or washout | 418 | $15,723 | $28 |
| New patient visit (60+ min) | 100 | $15,321 | $153 |
| Test for exercise-induced spasm of lung airways | 206 | $14,518 | $62 |
| Test to measure expiratory airflow and volume | 447 | $10,557 | $17 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 79 | $10,390 | $75 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 12 | $9,547 | $52 |
| Ct scan of chest without contrast | 81 | $5,208 | $55 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 21 | $3,174 | $144 |
| X-ray of chest, 2 views | 160 | $2,892 | $15 |
| Telephone medical discussion with physician, 21-30 minutes | 38 | $2,567 | $64 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 30 | $2,102 | $49 |
| Long return visit (40+ min) | 12 | $1,657 | $127 |
| Irrigation and suction of lung airways to obtain cells using an endoscope | 16 | $1,337 | $79 |
| Blood test, comprehensive group of blood chemicals | 67 | $762 | $10 |
| Smoking and tobacco use intensive counseling, more than 10 minutes | 22 | $706 | $26 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 66 | $530 | $8 |
| Blood test, thyroid stimulating hormone (tsh) | 27 | $447 | $17 |
| Blood gases measurement | 12 | $311 | $26 |
| Measurement c-reactive protein for detection of infection or inflammation | 58 | $298 | $5 |
| Insertion of needle into vein for collection of blood sample | 85 | $294 | $3 |
| Injection of drug or substance under skin or into muscle | 16 | $154 | $10 |
| Injection, methylprednisolone acetate, 40 mg | 15 | $75 | None |
2021: 28 services
| Return visit (30+ min) | 500 | $77,784 | $90 |
| Critical care, first 30-74 minutes | 103 | $43,984 | $164 |
| Test to examine how well the lungs exchange gases | 481 | $23,638 | $37 |
| Test for exercise-induced spasm of lung airways | 278 | $19,826 | $57 |
| Test to determine lung volumes using gas dilution or washout | 476 | $17,972 | $28 |
| Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | 140 | $16,349 | $29 |
| New patient visit (60+ min) | 87 | $13,866 | $159 |
| Test to measure expiratory airflow and volume | 503 | $13,682 | $19 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 16 | $9,980 | $55 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 90 | $9,902 | $53 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 55 | $8,655 | $149 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 65 | $7,164 | $77 |
| Ct scan of chest without contrast | 103 | $6,511 | $55 |
| Long return visit (40+ min) | 30 | $3,882 | $125 |
| X-ray of chest, 2 views | 201 | $3,431 | $15 |
| Irrigation and suction of lung airways to obtain cells using an endoscope | 31 | $2,381 | $74 |
| Ultrasound scan of chest | 26 | $1,976 | $47 |
| Short return visit (20+ min) | 11 | $739 | $67 |
| Smoking and tobacco use intensive counseling, more than 10 minutes | 20 | $727 | $26 |
| Blood test, comprehensive group of blood chemicals | 55 | $634 | $11 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 62 | $505 | $8 |
| Blood test, thyroid stimulating hormone (tsh) | 26 | $470 | $17 |
| Insertion of needle into vein for collection of blood sample | 85 | $300 | $3 |
| Measurement c-reactive protein for detection of infection or inflammation | 49 | $250 | $5 |
| Injection of drug or substance under skin or into muscle | 19 | $227 | $10 |
| X-ray of chest, 1 view | 12 | $172 | $11 |
| Injection, methylprednisolone acetate, 40 mg | 18 | $95 | None |
| Exam of lung airways using an endoscope | 25 | $34 | $1 |
2020: 33 services
| Injection, mepolizumab, 1 mg | 11 | $243,077 | None |
| Return visit (30+ min) | 501 | $64,230 | $75 |
| Critical care, first 30-74 minutes | 106 | $46,573 | $169 |
| Test to examine how well the lungs exchange gases | 439 | $19,526 | $36 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 167 | $17,876 | $54 |
| Test to determine lung volumes using gas dilution or washout | 435 | $15,207 | $29 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 101 | $14,858 | $147 |
| New patient visit (60+ min) | 88 | $13,073 | $149 |
| Test to measure expiratory airflow and volume | 427 | $12,159 | $24 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 16 | $10,484 | $54 |
| Telephone medical discussion with physician, 21-30 minutes | 110 | $9,145 | $77 |
| Test for exercise-induced spasm of lung airways | 170 | $8,782 | $51 |
| Ct scan of chest without contrast | 109 | $7,642 | $61 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 65 | $7,028 | $79 |
| Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | 98 | $6,111 | $31 |
| Irrigation and suction of lung airways to obtain cells using an endoscope | 46 | $4,473 | $88 |
| X-ray of chest, 2 views | 214 | $3,438 | $14 |
| Long return visit (40+ min) | 21 | $2,519 | $110 |
| Ct scan of blood vessels of chest with contrast | 11 | $1,160 | $105 |
| Influenza vaccine split virus, preservative free | 20 | $1,015 | $51 |
| Ultrasound scan of chest | 16 | $1,002 | $56 |
| Short return visit (20+ min) | 16 | $779 | $49 |
| Blood test, comprehensive group of blood chemicals | 61 | $663 | $10 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 62 | $511 | $8 |
| Blood test, thyroid stimulating hormone (tsh) | 23 | $385 | $17 |
| Detection test by immunoassay with direct visual observation for influenza virus | 11 | $351 | $15 |
| Administration of influenza virus vaccine | 21 | $339 | $15 |
| Insertion of needle into vein for collection of blood sample | 88 | $301 | $3 |
| Measurement c-reactive protein for detection of infection or inflammation | 55 | $275 | $5 |
| Injection of drug or substance under skin or into muscle | 21 | $229 | $9 |
| Injection, methylprednisolone acetate, 40 mg | 22 | $96 | None |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 11 | $89 | $0 |
| Exam of lung airways using an endoscope | 39 | $64 | $2 |
2019: 35 services
| Injection, mepolizumab, 1 mg | 11 | $211,218 | None |
| Return visit (30+ min) | 551 | $75,391 | $78 |
| Critical care, first 30-74 minutes | 148 | $61,350 | $171 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 270 | $35,316 | $56 |
| Test to examine how well the lungs exchange gases | 571 | $30,309 | $37 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 186 | $28,729 | $154 |
| Test to determine lung volumes using gas dilution or washout | 543 | $21,749 | $29 |
| Test to measure expiratory airflow and volume | 571 | $19,699 | $24 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 16 | $10,920 | $57 |
| New patient visit (60+ min) | 68 | $10,375 | $153 |
| Ct scan of chest without contrast | 125 | $9,904 | $67 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 56 | $6,696 | $80 |
| New patient visit (45+ min) | 42 | $5,146 | $123 |
| X-ray of chest, 2 views | 312 | $4,942 | $13 |
| Irrigation and suction of lung airways to obtain cells using an endoscope | 43 | $3,829 | $83 |
| Ct scan of blood vessels of chest with contrast | 12 | $1,685 | $140 |
| Long return visit (40+ min) | 12 | $1,313 | $109 |
| Measurement of antibody for assessment of autoimmune disorder, any method | 12 | $977 | $20 |
| Blood test, comprehensive group of blood chemicals | 64 | $932 | $12 |
| Short return visit (20+ min) | 17 | $887 | $52 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 74 | $728 | $8 |
| Blood test, thyroid stimulating hormone (tsh) | 38 | $695 | $18 |
| Injection of drug or substance under skin or into muscle | 32 | $457 | $12 |
| Measurement c-reactive protein for detection of infection or inflammation | 65 | $366 | $6 |
| Insertion of needle into vein for collection of blood sample | 99 | $359 | $3 |
| Test for exercise-induced lung stress | 14 | $346 | $25 |
| Administration of influenza virus vaccine | 13 | $197 | $15 |
| X-ray of chest, 1 view | 11 | $154 | $11 |
| Injection, methylprednisolone acetate, 40 mg | 28 | $149 | None |
| Injection, methylprednisolone acetate, 80 mg | 16 | $138 | None |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 12 | $109 | $0 |
| Exam of lung airways using an endoscope | 37 | $108 | $3 |
| Creatine kinase (cardiac enzyme) level, total | 11 | $78 | $7 |
| Blood creatinine level | 13 | $73 | $6 |
| Red blood cell sedimentation rate, to detect inflammation, automated | 12 | $35 | $3 |
2018: 36 services
| Injection, mepolizumab, 1 mg | 11 | $182,159 | None |
| Return visit (30+ min) | 591 | $80,262 | $74 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 316 | $55,965 | $54 |
| Critical care, first 30-74 minutes | 115 | $40,116 | $167 |
| Test to examine how well the lungs exchange gases | 577 | $30,979 | $37 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 170 | $28,879 | $151 |
| Test to determine lung volumes using gas dilution or washout | 565 | $24,218 | $29 |
| Test to measure expiratory airflow and volume | 583 | $20,211 | $23 |
| New patient visit (45+ min) | 140 | $16,077 | $115 |
| Ct scan of chest without contrast | 161 | $12,902 | $65 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 20 | $11,409 | $56 |
| X-ray of chest, 2 views | 464 | $7,328 | $13 |
| New patient visit (60+ min) | 50 | $6,682 | $134 |
| Irrigation and suction of lung airways to obtain cells using an endoscope | 49 | $4,703 | $87 |
| Blood test, thyroid stimulating hormone (tsh) | 126 | $2,643 | $20 |
| Ct scan of blood vessels of chest with contrast | 15 | $2,143 | $143 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 22 | $2,124 | $79 |
| Blood test, comprehensive group of blood chemicals | 151 | $2,065 | $13 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 173 | $1,744 | $9 |
| Short return visit (20+ min) | 31 | $1,494 | $47 |
| Influenza vaccine split virus, preservative free | 27 | $1,387 | $51 |
| Long return visit (40+ min) | 11 | $1,180 | $107 |
| Ultrasound scan of chest | 16 | $1,176 | $62 |
| Measurement c-reactive protein for detection of infection or inflammation | 158 | $1,003 | $6 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 16 | $979 | $45 |
| Injection of drug or substance under skin or into muscle | 60 | $961 | $14 |
| Injection, methylprednisolone acetate, 80 mg | 64 | $664 | None |
| Insertion of needle into vein for collection of blood sample | 187 | $659 | $3 |
| Administration of influenza virus vaccine | 30 | $555 | $19 |
| Detection test by immunoassay with direct visual observation for influenza virus | 15 | $243 | $16 |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 20 | $223 | $0 |
| X-ray of chest, 1 view | 20 | $194 | $8 |
| Injection, methylprednisolone acetate, 40 mg | 19 | $99 | None |
| Blood creatinine level | 13 | $87 | $6 |
| Injection, methylprednisolone sodium succinate, up to 125 mg | 12 | $57 | None |
| Injection, ceftriaxone sodium, per 250 mg | 11 | $16 | None |
2017: 50 services
| Injection, mepolizumab, 1 mg | 11 | $144,707 | None |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 416 | $81,222 | $54 |
| Critical care, first 30-74 minutes | 204 | $80,621 | $164 |
| Return visit (30+ min) | 517 | $73,300 | $74 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 189 | $29,657 | $149 |
| Test to examine how well the lungs exchange gases | 482 | $26,878 | $36 |
| Test to determine lung volumes using gas dilution or washout | 477 | $20,035 | $28 |
| New patient visit (60+ min) | 121 | $17,656 | $146 |
| Test to measure expiratory airflow and volume | 486 | $17,147 | $23 |
| Ct scan of chest without contrast | 158 | $13,484 | $70 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 17 | $12,527 | $51 |
| New patient visit (45+ min) | 72 | $8,108 | $113 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 68 | $7,505 | $74 |
| Pulmonary exercise testing | 152 | $5,856 | $38 |
| Vitamin d-3 level | 136 | $5,851 | $40 |
| Irrigation and suction of lung airways to obtain cells using an endoscope | 80 | $5,276 | $64 |
| Ultrasound scan of chest | 54 | $5,231 | $57 |
| X-ray of chest, 2 views, front and side | 347 | $4,960 | $11 |
| Blood test, thyroid stimulating hormone (tsh) | 140 | $3,253 | $23 |
| Aspiration of fluid from chest cavity using imaging guidance | 12 | $3,007 | $215 |
| Exam of lung airways and sampling of lymph nodes using an endoscope and ultrasound guidance, 1-2 lymph nodes | 18 | $2,860 | $159 |
| Blood test, comprehensive group of blood chemicals | 178 | $2,677 | $14 |
| Needle biopsy of windpipe cartilage, airway, and/or lung using an endoscope | 21 | $2,639 | $126 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 208 | $2,341 | $10 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 30 | $2,205 | $45 |
| Short return visit (20+ min) | 45 | $2,204 | $49 |
| Pneumococcal vaccine, 13-valent | 11 | $1,888 | $172 |
| Long return visit (40+ min) | 17 | $1,554 | $91 |
| Ct scan of chest with contrast | 13 | $1,494 | $115 |
| Insertion of non-tunneled central venous tube for infusion (5 years or older) | 16 | $1,468 | $92 |
| Influenza vaccine split virus, preservative free | 30 | $1,387 | $46 |
| Ultrasound study of arm or leg veins with compression and maneuvers | 11 | $1,346 | $112 |
| Measurement c-reactive protein for detection of infection or inflammation | 184 | $1,315 | $7 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 13 | $1,203 | $28 |
| Biopsy of lobe of lung using an endoscope, 1 lobe | 14 | $1,089 | $78 |
| Insertion of needle into vein for collection of blood sample | 255 | $961 | $3 |
| Administration of influenza virus vaccine | 38 | $840 | $22 |
| Injection of drug or substance into vein | 15 | $599 | $37 |
| Administration of pneumococcal vaccine | 18 | $409 | $23 |
| Injection of additional new drug or substance into vein | 19 | $302 | $14 |
| Smoking and tobacco use intensive counseling, 4-10 minutes | 19 | $285 | $13 |
| Injection of drug or substance under skin or into muscle | 14 | $254 | $18 |
| Red blood cell sedimentation rate, to detect inflammation, automated | 55 | $200 | $4 |
| X-ray of chest, 1 view, front | 18 | $184 | $9 |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 18 | $176 | $0 |
| Injection, methylprednisolone sodium succinate, up to 125 mg | 33 | $143 | None |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 13 | $121 | $9 |
| Blood test, clotting time | 18 | $100 | $5 |
| Exam of lung airways using an endoscope | 29 | $62 | $2 |
| Injection, ceftriaxone sodium, per 250 mg | 12 | $25 | None |
2016: 40 services
| Return visit (30+ min) | 440 | $68,737 | $76 |
| Critical care, first 30-74 minutes | 185 | $64,399 | $166 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 308 | $50,314 | $53 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 243 | $39,019 | $77 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 158 | $25,027 | $147 |
| Test to examine how well the lungs exchange gases | 365 | $19,755 | $37 |
| New patient visit (60+ min) | 116 | $16,461 | $142 |
| Test to measure expiratory airflow and volume | 408 | $15,605 | $24 |
| Test to determine lung volumes using gas dilution or washout | 360 | $14,716 | $28 |
| Ct scan of chest without contrast | 138 | $11,670 | $72 |
| X-ray of chest, 2 views, front and side | 398 | $9,485 | $16 |
| Blood test, comprehensive group of blood chemicals | 355 | $7,897 | $14 |
| Vitamin d-3 level | 169 | $7,706 | $40 |
| Pulmonary exercise testing | 173 | $6,660 | $35 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 59 | $5,996 | $47 |
| Blood test, thyroid stimulating hormone (tsh) | 253 | $5,922 | $22 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 359 | $5,670 | $10 |
| Ultrasound scan of chest | 69 | $5,436 | $57 |
| Long return visit (40+ min) | 41 | $4,960 | $106 |
| Irrigation and suction of lung airways to obtain cells using an endoscope | 50 | $3,865 | $73 |
| New patient visit (45+ min) | 25 | $2,787 | $111 |
| Exam of lung airways and sampling of lymph nodes using an endoscope and ultrasound guidance, 1-2 lymph nodes | 14 | $2,401 | $171 |
| Short return visit (20+ min) | 43 | $2,319 | $52 |
| Measurement c-reactive protein for detection of infection or inflammation | 282 | $1,975 | $7 |
| Insertion of needle into vein for collection of blood sample | 366 | $1,764 | $3 |
| Injection of additional new drug or substance into vein | 48 | $1,639 | $15 |
| Measurement of antibody for assessment of autoimmune disorder, any method | 11 | $1,245 | $24 |
| Red blood cell sedimentation rate, to detect inflammation, automated | 280 | $1,025 | $4 |
| Insertion of non-tunneled central venous tube for infusion (5 years or older) | 11 | $1,007 | $92 |
| Injection of drug or substance into vein | 17 | $746 | $39 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 15 | $579 | $13 |
| Influenza vaccine split virus, preservative free | 13 | $525 | $40 |
| Injection, meropenem, 100 mg | 11 | $452 | None |
| Injection, methylprednisolone sodium succinate, up to 125 mg | 62 | $446 | None |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 11 | $381 | $29 |
| Administration of influenza virus vaccine | 16 | $356 | $22 |
| X-ray of chest, 1 view, front | 15 | $230 | $13 |
| Injection, azithromycin, 500 mg | 35 | $133 | None |
| Exam of lung airways using an endoscope | 35 | $79 | $2 |
| Injection, levofloxacin, 250 mg | 16 | $77 | None |
2015: 30 services
| Critical care, first 30-74 minutes | 126 | $54,332 | $166 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 211 | $26,637 | $53 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 140 | $19,673 | $77 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 91 | $13,939 | $145 |
| New patient visit (60+ min) | 50 | $7,176 | $144 |
| Return visit (30+ min) | 55 | $5,727 | $78 |
| Return visit (30+ min) | 67 | $3,377 | $47 |
| New patient visit (60+ min) | 22 | $2,490 | $113 |
| Test to examine how well the lungs exchange gases | 61 | $2,253 | $37 |
| Test to measure expiratory airflow and volume | 63 | $1,616 | $24 |
| New patient visit (45+ min) | 14 | $1,614 | $115 |
| Irrigation and suction of lung airways to obtain cells using an endoscope | 21 | $1,596 | $73 |
| Test to determine lung volumes using gas dilution or washout | 54 | $1,544 | $29 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 14 | $1,432 | $102 |
| Short return visit (20+ min) | 36 | $1,248 | $35 |
| Ct scan of chest without contrast | 15 | $1,222 | $81 |
| X-ray of chest, 2 views, front and side | 60 | $756 | $11 |
| Blood test, comprehensive group of blood chemicals | 41 | $671 | $13 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 36 | $487 | $10 |
| Pulmonary exercise testing | 19 | $365 | $19 |
| Blood test, thyroid stimulating hormone (tsh) | 16 | $359 | $22 |
| Test to determine lung volumes using sensors | 37 | $276 | $7 |
| Measurement c-reactive protein for detection of infection or inflammation | 33 | $235 | $7 |
| Test to examine how well the lungs exchange gases | 38 | $204 | $5 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 25 | $198 | $8 |
| Insertion of needle into vein for collection of blood sample | 45 | $182 | $3 |
| Red blood cell sedimentation rate, to detect inflammation, automated | 33 | $123 | $4 |
| Smoking and tobacco use intensive counseling, 4-10 minutes | 12 | $111 | $9 |
| Test to measure rate of airflow | 11 | $90 | $8 |
| Exam of lung airways using an endoscope | 14 | $24 | $2 |
2014: 20 services
| Critical care, first 30-74 minutes | 86 | $43,314 | $163 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 127 | $20,660 | $53 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 74 | $11,962 | $146 |
| Return visit (30+ min) | 66 | $6,219 | $72 |
| Return visit (30+ min) | 95 | $6,210 | $58 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 44 | $4,490 | $76 |
| New patient visit (60+ min) | 24 | $3,488 | $145 |
| New patient visit (60+ min) | 24 | $2,938 | $122 |
| Needle biopsy of windpipe cartilage, airway, and/or lung using an endoscope | 11 | $1,597 | $145 |
| Long return visit (40+ min) | 13 | $1,360 | $105 |
| Test to determine lung volumes using sensors | 99 | $970 | $9 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 87 | $872 | $10 |
| Short return visit (20+ min) | 21 | $835 | $38 |
| Pulmonary exercise testing | 19 | $747 | $36 |
| Biopsy of lobe of lung using an endoscope, 1 lobe | 11 | $708 | $64 |
| Test to examine how well the lungs exchange gases | 94 | $658 | $7 |
| Pulmonary exercise testing | 25 | $582 | $23 |
| Short return visit (20+ min) | 13 | $578 | $44 |
| Irrigation and suction of lung airways to obtain cells using an endoscope | 13 | $355 | $27 |
| Test to measure rate of airflow | 28 | $309 | $11 |
2013: 14 services
| Critical care, first 30-74 minutes | 34 | $19,373 | $160 |
| New patient visit (60+ min) | 41 | $5,991 | $146 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 35 | $5,654 | $145 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 47 | $4,958 | $52 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 26 | $2,827 | $74 |
| Return visit (30+ min) | 31 | $2,686 | $77 |
| Long return visit (40+ min) | 17 | $2,059 | $103 |
| Biopsy of lobe of lung using an endoscope, 1 lobe | 15 | $1,179 | $74 |
| Computer-assisted image-guided navigation of lung airways using an endoscope | 11 | $775 | $70 |
| Pulmonary exercise testing | 18 | $772 | $41 |
| Irrigation and suction of lung airways to obtain cells using an endoscope | 14 | $565 | $40 |
| Test to determine lung volumes using sensors | 56 | $537 | $10 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 48 | $471 | $10 |
| Test to examine how well the lungs exchange gases | 57 | $401 | $7 |
Medicaid work
$116,702 in 2024
Medicaid paid $116,702 for 3,137 billed services this clinician did in 2024, up to 69 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes | 967 | $66,365 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 1,234 | $31,671 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 850 | $16,133 |
| 1ST HOSP IP/OBS HIGH 75 | 61 | $2,506 |
| SBSQ NURSING FACILITY CARE LOW MDM 20 MINUTES | 25 | $27 |
| 2024 | 3,137 | 5 | 69 | $116,702 |
| 2023 | 1,977 | 5 | 54 | $64,915 |
| 2022 | 97 | 1 | 17 | $1,969 |
| 2021 | 117 | 1 | 17 | $2,482 |
| 2020 | 250 | 4 | 16 | $3,413 |
| 2019 | 362 | 6 | 17 | $1,679 |
| 2018 | 571 | 5 | 24 | $9,293 |
See the largest Medicaid services in earlier years
2023
| Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes | 645 | $37,812 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 568 | $11,959 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 581 | $9,367 |
| 1ST HOSP IP/OBS HIGH 75 | 110 | $4,069 |
| Return visit (30+ min) | 73 | $1,708 |
2022
| Return visit (30+ min) | 97 | $1,969 |
2021
| Return visit (30+ min) | 117 | $2,482 |
2020
| Diffusing capacity | 72 | $1,520 |
| Return visit (30+ min) | 61 | $808 |
| Spirometry, including graphic record, total and timed vital capacity, expiratory flow rate measurement(s), with or without maximal voluntary ventilation | 74 | $702 |
| Gas dilution or washout for determination of lung volumes and, when performed, distribution of ventilation and closing volumes | 43 | $383 |
2019
| Return visit (30+ min) | 128 | $643 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 119 | $300 |
| 1ST HOSP IP/OBS HIGH 75 | 21 | $284 |
| Diffusing capacity | 31 | $219 |
| Gas dilution or washout for determination of lung volumes and, when performed, distribution of ventilation and closing volumes | 32 | $195 |
| Spirometry, including graphic record, total and timed vital capacity, expiratory flow rate measurement(s), with or without maximal voluntary ventilation | 31 | $38 |
2018
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 317 | $6,863 |
| Return visit (30+ min) | 145 | $1,648 |
| Spirometry, including graphic record, total and timed vital capacity, expiratory flow rate measurement(s), with or without maximal voluntary ventilation | 47 | $620 |
| Diffusing capacity | 31 | $126 |
| Gas dilution or washout for determination of lung volumes and, when performed, distribution of ventilation and closing volumes | 31 | $37 |
Drugs they prescribed that Part D paid
$136,964
Pharmacies billed $136,964 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 496) in 2024. At or below the middle of the specialty; the typical pulmonary disease clinician is at 0%.
0 generic and 292 brand-name prescriptions · $136,964 in drug cost · 16 antibiotic prescriptions to 12 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Trelegy Ellipta | 98 | $65,717 | $671 |
| Anoro Ellipta | 53 | $25,082 | $473 |
| Breo Ellipta | 26 | $11,503 | $442 |
| Breyna | 13 | $2,775 | $213 |
| Fluticasone-Salmeterol | 12 | $1,337 | $111 |
See all 11 drugs
| Trelegy Ellipta | 98 | $65,717 | $671 |
| Anoro Ellipta | 53 | $25,082 | $473 |
| Breo Ellipta | 26 | $11,503 | $442 |
| Breyna | 13 | $2,775 | $213 |
| Fluticasone-Salmeterol | 12 | $1,337 | $111 |
| Albuterol Sulfate Hfa | 58 | $1,250 | $22 |
| Ventolin Hfa | 11 | $595 | $54 |
| Montelukast | 73 | $325 | $4 |
| Theophylline Er | 13 | $205 | $16 |
| Fluticasone Propionate | 14 | $149 | $11 |
| Hydroxyzine | 15 | $71 | $5 |
Year by year
| 2024 | 496 | 143 | 0% (0) | 59% | $136,964 |
| 2023 | 2,196 | 308 | 0% (0) | 57% | $1,285,073 |
| 2022 | 3,069 | 369 | 0% (0) | None | $1,583,288 |
| 2021 | 3,083 | 381 | 0% (0) | 51% | $1,360,630 |
| 2020 | 2,843 | 372 | None | 54% | $1,359,354 |
| 2019 | 2,777 | 352 | 0% (0) | 53% | $1,247,505 |
| 2018 | 2,516 | 353 | None | 49% | $828,086 |
| 2017 | 2,505 | 330 | 0% (0) | 44% | $666,121 |
| 2016 | 1,807 | 295 | None | 43% | $286,855 |
| 2015 | 773 | 142 | None | 57% | $193,773 |
| 2014 | 578 | 124 | None | 56% | $132,222 |
| 2013 | 103 | 32 | None | 59% | $13,951 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 33 drugs
| Ofev | 30 | $349,849 | $11,662 |
| Trelegy Ellipta | 280 | $228,643 | $817 |
| Adempas | 11 | $131,028 | $11,912 |
| Anoro Ellipta | 185 | $102,190 | $552 |
| Breo Ellipta | 162 | $85,744 | $529 |
| Nucala | 19 | $72,377 | $3,809 |
| Symbicort | 111 | $61,424 | $553 |
| Stiolto Respimat | 49 | $28,352 | $579 |
| Spiriva Respimat | 23 | $24,640 | $1,071 |
| Ambrisentan | 14 | $22,795 | $1,628 |
| Advair Diskus | 39 | $19,765 | $507 |
| Spiriva Handihaler | 32 | $18,551 | $580 |
| Combivent Respimat | 27 | $17,834 | $661 |
| Eliquis | 26 | $16,438 | $632 |
| Breztri Aerosphere | 17 | $14,256 | $839 |
| Flovent Hfa | 24 | $9,506 | $396 |
| Xarelto | 16 | $8,892 | $556 |
| Advair Hfa | 15 | $8,612 | $574 |
| Fluticasone-Salmeterol | 16 | $7,644 | $478 |
| Albuterol Sulfate Hfa | 155 | $5,198 | $34 |
| Roflumilast | 18 | $4,954 | $275 |
| Theophylline Er | 123 | $4,477 | $36 |
| Budesonide-Formoterol | 11 | $4,100 | $373 |
| Montelukast | 323 | $4,067 | $13 |
| Fluticasone Propionate | 81 | $1,536 | $19 |
| Ventolin Hfa | 20 | $1,230 | $62 |
| Azithromycin | 35 | $604 | $17 |
| Hydroxyzine | 35 | $391 | $11 |
| Doxycycline Hyclate | 23 | $229 | $10 |
| Prednisone | 60 | $207 | $3 |
| Pantoprazole | 15 | $195 | $13 |
| Omeprazole | 20 | $113 | $6 |
| Levofloxacin | 14 | $87 | $6 |
2022: 38 drugs
| Ofev | 40 | $433,923 | $10,848 |
| Trelegy Ellipta | 297 | $236,380 | $796 |
| Adempas | 16 | $199,345 | $12,459 |
| Breo Ellipta | 311 | $149,562 | $481 |
| Anoro Ellipta | 233 | $122,643 | $526 |
| Nucala | 26 | $92,037 | $3,540 |
| Symbicort | 82 | $44,877 | $547 |
| Spiriva Respimat | 38 | $28,181 | $742 |
| Stiolto Respimat | 40 | $23,954 | $599 |
| Combivent Respimat | 40 | $23,201 | $580 |
| Advair Diskus | 51 | $22,231 | $436 |
| Daliresp | 24 | $17,172 | $716 |
| Breztri Aerosphere | 17 | $16,275 | $957 |
| Advair Hfa | 17 | $16,224 | $954 |
| Eliquis | 24 | $13,198 | $550 |
| Xarelto | 19 | $11,722 | $617 |
| Fluticasone-Salmeterol | 25 | $11,702 | $468 |
| Albuterol Sulfate Hfa | 208 | $10,443 | $50 |
| Flovent Hfa | 21 | $8,664 | $413 |
| Montelukast | 496 | $8,058 | $16 |
| Spiriva Handihaler | 11 | $5,676 | $516 |
| Arnuity Ellipta | 25 | $5,194 | $208 |
| Theophylline | 156 | $2,897 | $19 |
| Flovent Diskus | 12 | $2,766 | $231 |
| Fluticasone Propionate | 139 | $2,396 | $17 |
| Ventolin Hfa | 21 | $1,999 | $95 |
| Doxycycline Hyclate | 83 | $1,152 | $14 |
| Azithromycin | 55 | $812 | $15 |
| Prednisone | 173 | $734 | $4 |
| Levofloxacin | 51 | $579 | $11 |
| Hydroxyzine | 33 | $356 | $11 |
| Azelastine | 15 | $350 | $23 |
| Methylphenidate | 16 | $316 | $20 |
| Pantoprazole | 15 | $289 | $19 |
| Omeprazole | 21 | $258 | $12 |
| Rifampin | 12 | $238 | $20 |
| Methotrexate | 14 | $103 | $7 |
| Levothyroxine | 25 | $83 | $3 |
2021: 44 drugs
| Adempas | 19 | $255,229 | $13,433 |
| Ofev | 30 | $253,925 | $8,464 |
| Trelegy Ellipta | 286 | $210,662 | $737 |
| Breo Ellipta | 347 | $157,270 | $453 |
| Anoro Ellipta | 192 | $108,687 | $566 |
| Nucala | 22 | $74,857 | $3,403 |
| Symbicort | 86 | $42,394 | $493 |
| Advair Diskus | 68 | $29,371 | $432 |
| Daliresp | 41 | $22,649 | $552 |
| Stiolto Respimat | 36 | $21,290 | $591 |
| Eliquis | 38 | $19,640 | $517 |
| Combivent Respimat | 24 | $17,536 | $731 |
| Albuterol Sulfate Hfa | 223 | $12,586 | $56 |
| Spiriva Respimat | 18 | $11,651 | $647 |
| Xarelto | 16 | $11,015 | $688 |
| Advair Hfa | 11 | $9,705 | $882 |
| Spiriva | 14 | $6,943 | $496 |
| Wixela Inhub | 15 | $6,469 | $431 |
| Montelukast | 491 | $5,685 | $12 |
| Incruse Ellipta | 14 | $5,293 | $378 |
| Flovent Hfa | 12 | $4,930 | $411 |
| Fluticasone-Salmeterol | 23 | $4,917 | $214 |
| Budesonide-Formoterol | 13 | $4,800 | $369 |
| Arnuity Ellipta | 19 | $4,022 | $212 |
| Ventolin Hfa | 45 | $3,388 | $75 |
| Fluticasone Propionate | 178 | $2,961 | $17 |
| Flovent Diskus | 12 | $2,523 | $210 |
| Theophylline | 107 | $2,218 | $21 |
| Azithromycin | 77 | $1,061 | $14 |
| Prednisone | 171 | $916 | $5 |
| Doxycycline Hyclate | 50 | $894 | $18 |
| Rifampin | 17 | $811 | $48 |
| Azelastine | 17 | $800 | $47 |
| Methotrexate | 24 | $420 | $18 |
| Nystatin | 11 | $380 | $35 |
| Levofloxacin | 49 | $379 | $8 |
| Methylphenidate | 13 | $342 | $26 |
| Ethambutol | 11 | $273 | $25 |
| Warfarin | 11 | $233 | $21 |
| Hydroxyzine | 31 | $181 | $6 |
| Omeprazole | 24 | $145 | $6 |
| Potassium Chloride | 13 | $138 | $11 |
| Levothyroxine | 16 | $82 | $5 |
| Furosemide | 14 | $38 | $3 |
2020: 37 drugs
| Ofev | 51 | $445,854 | $8,742 |
| Adempas | 12 | $148,701 | $12,392 |
| Trelegy Ellipta | 208 | $146,642 | $705 |
| Anoro Ellipta | 273 | $143,799 | $527 |
| Breo Ellipta | 329 | $136,709 | $416 |
| Symbicort | 97 | $54,782 | $565 |
| Nucala | 12 | $39,522 | $3,293 |
| Advair Diskus | 60 | $28,102 | $468 |
| Combivent Respimat | 43 | $22,883 | $532 |
| Daliresp | 42 | $20,469 | $487 |
| Eliquis | 37 | $18,111 | $489 |
| Spiriva Respimat | 24 | $11,955 | $498 |
| Stiolto Respimat | 19 | $9,141 | $481 |
| Xarelto | 14 | $8,107 | $579 |
| Spiriva | 17 | $8,102 | $477 |
| Albuterol Sulfate Hfa | 103 | $7,013 | $68 |
| Arnuity Ellipta | 23 | $6,417 | $279 |
| Incruse Ellipta | 15 | $6,033 | $402 |
| Proair Hfa | 56 | $6,015 | $107 |
| Fluticasone-Salmeterol | 25 | $4,235 | $169 |
| Montelukast | 417 | $4,103 | $10 |
| Ventolin Hfa | 43 | $2,821 | $66 |
| Fluticasone Propionate | 175 | $2,366 | $14 |
| Doxycycline Hyclate | 77 | $1,820 | $24 |
| Theophylline | 75 | $1,661 | $22 |
| Azithromycin | 88 | $1,580 | $18 |
| Azelastine | 19 | $1,473 | $78 |
| Prednisone | 162 | $813 | $5 |
| Methylphenidate | 17 | $603 | $35 |
| Nystatin | 17 | $448 | $26 |
| Hydroxyzine | 49 | $399 | $8 |
| Omeprazole | 26 | $296 | $11 |
| Levofloxacin | 33 | $220 | $7 |
| Methotrexate | 11 | $173 | $16 |
| Potassium Chloride | 13 | $163 | $13 |
| Levothyroxine | 14 | $98 | $7 |
| Furosemide | 12 | $19 | $2 |
2019: 41 drugs
| Ofev | 64 | $538,187 | $8,409 |
| Breo Ellipta | 329 | $128,342 | $390 |
| Anoro Ellipta | 238 | $111,955 | $470 |
| Trelegy Ellipta | 112 | $64,051 | $572 |
| Symbicort | 104 | $50,800 | $488 |
| Nucala | 13 | $41,484 | $3,191 |
| Advair Diskus | 57 | $24,248 | $425 |
| Combivent Respimat | 56 | $23,683 | $423 |
| Daliresp | 56 | $22,550 | $403 |
| Eliquis | 28 | $14,191 | $507 |
| Spiriva Respimat | 26 | $14,000 | $538 |
| Spiriva | 30 | $13,344 | $445 |
| Incruse Ellipta | 25 | $9,168 | $367 |
| Stiolto Respimat | 21 | $8,731 | $416 |
| Xarelto | 14 | $7,846 | $560 |
| Proair Hfa | 75 | $7,596 | $101 |
| Arnuity Ellipta | 39 | $6,853 | $176 |
| Montelukast | 352 | $4,329 | $12 |
| Ventolin Hfa | 54 | $3,826 | $71 |
| Fluticasone-Salmeterol | 17 | $3,222 | $190 |
| Fluticasone Propionate | 169 | $2,322 | $14 |
| Azithromycin | 99 | $1,702 | $17 |
| Azelastine | 18 | $1,464 | $81 |
| Theo-24 | 17 | $1,372 | $81 |
| Prednisone | 178 | $1,244 | $7 |
| Theophylline | 44 | $1,008 | $23 |
| Rifampin | 26 | $997 | $38 |
| Sildenafil Citrate | 11 | $849 | $77 |
| Methylphenidate | 28 | $799 | $29 |
| Albuterol Sulfate Hfa | 12 | $786 | $66 |
| Doxycycline Hyclate | 43 | $723 | $17 |
| Hydroxyzine | 68 | $566 | $8 |
| Ipratropium | 12 | $493 | $41 |
| Levofloxacin | 43 | $358 | $8 |
| Omeprazole | 30 | $250 | $8 |
| Levothyroxine | 37 | $244 | $7 |
| Ethambutol | 11 | $182 | $17 |
| Sulfamethoxazole-Trimethoprim | 13 | $138 | $11 |
| Potassium Chloride | 15 | $105 | $7 |
| Amitriptyline | 12 | $101 | $8 |
| Furosemide | 11 | $47 | $4 |
2018: 34 drugs
| Ofev | 33 | $202,342 | $6,132 |
| Breo Ellipta | 263 | $103,819 | $395 |
| Anoro Ellipta | 152 | $67,016 | $441 |
| Symbicort | 103 | $46,409 | $451 |
| Advair Diskus | 88 | $40,003 | $455 |
| Daliresp | 61 | $25,325 | $415 |
| Combivent Respimat | 50 | $23,317 | $466 |
| Spiriva | 38 | $16,802 | $442 |
| Trelegy Ellipta | 23 | $13,131 | $571 |
| Incruse Ellipta | 33 | $13,015 | $394 |
| Eliquis | 29 | $12,037 | $415 |
| Xarelto | 21 | $10,643 | $507 |
| Arnuity Ellipta | 43 | $8,667 | $202 |
| Ventolin Hfa | 113 | $7,438 | $66 |
| Spiriva Respimat | 13 | $5,144 | $396 |
| Stiolto Respimat | 12 | $4,455 | $371 |
| Montelukast | 355 | $3,204 | $9 |
| Fluticasone Propionate | 196 | $2,932 | $15 |
| Proair Hfa | 41 | $2,651 | $65 |
| Prednisone | 203 | $1,520 | $7 |
| Azithromycin | 96 | $1,412 | $15 |
| Theophylline | 35 | $1,335 | $38 |
| Hydroxyzine | 53 | $736 | $14 |
| Levofloxacin | 59 | $619 | $10 |
| Methylphenidate | 17 | $530 | $31 |
| Doxycycline Hyclate | 18 | $529 | $29 |
| Ipratropium | 13 | $430 | $33 |
| Levothyroxine | 52 | $371 | $7 |
| Potassium Chloride | 20 | $231 | $12 |
| Azathioprine | 11 | $230 | $21 |
| Pantoprazole | 11 | $164 | $15 |
| Furosemide | 46 | $155 | $3 |
| Omeprazole | 20 | $143 | $7 |
| Amitriptyline | 12 | $105 | $9 |
2017: 40 drugs
| Tracleer | 19 | $200,719 | $10,564 |
| Ofev | 15 | $91,774 | $6,118 |
| Anoro Ellipta | 119 | $49,874 | $419 |
| Advair Diskus | 115 | $48,995 | $426 |
| Breo Ellipta | 120 | $41,561 | $346 |
| Symbicort | 73 | $30,858 | $423 |
| Spiriva | 71 | $30,140 | $425 |
| Daliresp | 60 | $24,016 | $400 |
| Combivent Respimat | 50 | $17,396 | $348 |
| Eliquis | 23 | $8,677 | $377 |
| Incruse Ellipta | 25 | $8,268 | $331 |
| Proair Hfa | 81 | $6,538 | $81 |
| Stiolto Respimat | 17 | $6,392 | $376 |
| Ventolin Hfa | 100 | $5,755 | $58 |
| Chantix | 12 | $4,415 | $368 |
| Esomeprazole Magnesium | 14 | $4,012 | $287 |
| Montelukast | 334 | $3,031 | $9 |
| Pulmicort Flexhaler | 13 | $2,820 | $217 |
| Fluticasone Propionate | 178 | $2,240 | $13 |
| Theophylline Anhydrous | 21 | $2,168 | $103 |
| Prednisone | 300 | $2,023 | $7 |
| Clarithromycin | 16 | $1,948 | $122 |
| Azithromycin | 96 | $1,732 | $18 |
| Ipratropium | 26 | $566 | $22 |
| Rifampin | 15 | $549 | $37 |
| Doxycycline Hyclate | 14 | $533 | $38 |
| Hydroxyzine | 40 | $476 | $12 |
| Potassium Chloride | 38 | $416 | $11 |
| Levofloxacin | 60 | $412 | $7 |
| Bupropion Hcl Sr | 18 | $387 | $21 |
| Theophylline | 14 | $383 | $27 |
| Amoxicillin-Clavulanate Potass | 15 | $233 | $16 |
| Furosemide | 79 | $216 | $3 |
| Omeprazole | 21 | $206 | $10 |
| Levothyroxine | 23 | $181 | $8 |
| Azathioprine | 12 | $176 | $15 |
| Zaleplon | 14 | $130 | $9 |
| Sulfamethoxazole-Trimethoprim | 17 | $105 | $6 |
| Amitriptyline | 12 | $86 | $7 |
| Citalopram Hbr | 12 | $16 | $1 |
2016: 29 drugs
| Anoro Ellipta | 90 | $29,789 | $331 |
| Advair Diskus | 76 | $26,743 | $352 |
| Symbicort | 62 | $21,618 | $349 |
| Spiriva | 49 | $17,439 | $356 |
| Daliresp | 48 | $15,272 | $318 |
| Breo Ellipta | 46 | $13,944 | $303 |
| Combivent Respimat | 26 | $10,422 | $401 |
| Incruse Ellipta | 33 | $8,769 | $266 |
| Stiolto Respimat | 19 | $5,936 | $312 |
| Itraconazole | 21 | $5,758 | $274 |
| Eliquis | 13 | $4,711 | $362 |
| Proair Hfa | 57 | $4,541 | $80 |
| Chantix | 12 | $3,838 | $320 |
| Montelukast | 220 | $2,791 | $13 |
| Ventolin Hfa | 50 | $2,601 | $52 |
| Azithromycin | 115 | $1,723 | $15 |
| Prednisone | 241 | $1,440 | $6 |
| Fluticasone Propionate | 115 | $1,079 | $9 |
| Theophylline Anhydrous | 18 | $941 | $52 |
| Levofloxacin | 45 | $660 | $15 |
| Bupropion Hcl Sr | 24 | $586 | $24 |
| Ipratropium | 14 | $318 | $23 |
| Duloxetine | 12 | $255 | $21 |
| Omeprazole | 25 | $231 | $9 |
| Amoxicillin-Clavulanate Potass | 11 | $231 | $21 |
| Potassium Chloride | 21 | $213 | $10 |
| Furosemide | 60 | $177 | $3 |
| Levothyroxine | 17 | $114 | $7 |
| Klor-Con M20 | 12 | $24 | $2 |
2015: 16 drugs
| Symbicort | 75 | $22,236 | $296 |
| Spiriva | 68 | $21,806 | $321 |
| Advair Diskus | 63 | $20,991 | $333 |
| Daliresp | 55 | $10,178 | $185 |
| Combivent Respimat | 23 | $6,844 | $298 |
| Anoro Ellipta | 20 | $5,902 | $295 |
| Tudorza Pressair | 15 | $4,287 | $286 |
| Proair Hfa | 49 | $2,817 | $57 |
| Montelukast | 140 | $1,573 | $11 |
| Fluticasone Propionate | 76 | $859 | $11 |
| Ventolin Hfa | 18 | $838 | $47 |
| Prednisone | 36 | $213 | $6 |
| Bupropion Hcl Sr | 12 | $189 | $16 |
| Azithromycin | 14 | $104 | $7 |
| Levofloxacin | 12 | $65 | $5 |
| Omeprazole | 12 | $49 | $4 |
2014: 12 drugs
| Spiriva | 62 | $22,070 | $356 |
| Advair Diskus | 53 | $20,226 | $382 |
| Symbicort | 56 | $15,398 | $275 |
| Combivent Respimat | 20 | $5,550 | $278 |
| Daliresp | 32 | $5,371 | $168 |
| Montelukast | 108 | $2,115 | $20 |
| Proair Hfa | 32 | $1,586 | $50 |
| Fluticasone Propionate | 65 | $1,269 | $20 |
| Ventolin Hfa | 15 | $674 | $45 |
| Bupropion Hcl Sr | 13 | $322 | $25 |
| Azithromycin | 14 | $115 | $8 |
| Prednisone | 20 | $99 | $5 |
2013: 2 drugs
| Advair Diskus | 11 | $3,255 | $296 |
| Proair Hfa | 11 | $514 | $47 |
Money from drug and device companies
$422 in 2025
| 2025 | 4 | 26 | None | $422 |
| 2024 | 7 | 10 | None | $218 |
| 2023 | 10 | 35 | None | $632 |
| 2022 | 11 | 61 | None | $817 |
| 2021 | 10 | 61 | None | $748 |
| 2020 | 8 | 48 | None | $479 |
| 2019 | 3 | 3 | None | $59 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Insmed | Arikayce | $160 | 10 payments
|
| GlaxoSmithKline | Nucala | $156 | 11 payments
|
| Verona Pharma | Ohtuvayre | $60 | 2 payments
|
| Boehringer Ingelheim Pharmaceuticals | Ofev | $47 | 2 payments
|
See all 25 published payments
| Insmed | Meals · 2025-12-17 | Arikayce | $2 |
| Insmed | Meals · 2025-12-17 | Arikayce | $11 |
| Verona Pharma | Meals · 2025-12-17 | Ohtuvayre | $31 |
| GlaxoSmithKline | Meals · 2025-12-16 | Nucala | $7 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-11-12 | Jascayd | $22 |
| Insmed | Meals · 2025-11-11 | Arikayce | $24 |
| Insmed | Meals · 2025-11-05 | Arikayce | $2 |
| Insmed | Meals · 2025-11-05 | Arikayce | $12 |
| GlaxoSmithKline | Meals · 2025-11-04 | Trelegy Ellipta | $25 |
| GlaxoSmithKline | Meals · 2025-10-21 | Nucala | $25 |
| GlaxoSmithKline | Meals · 2025-09-30 | Nucala | $28 |
| Insmed | Meals · 2025-09-23 | Arikayce | $19 |
| GlaxoSmithKline | Meals · 2025-09-23 | Nucala | $6 |
| GlaxoSmithKline | Meals · 2025-09-02 | Trelegy Ellipta | $9 |
| Verona Pharma | Meals · 2025-08-27 | Ohtuvayre | $29 |
| Insmed | Meals · 2025-08-20 | Arikayce | $23 |
| GlaxoSmithKline | Meals · 2025-07-09 | Nucala | $16 |
| Insmed | Meals · 2025-06-04 | Arikayce | $31 |
| GlaxoSmithKline | Meals · 2025-05-21 | Nucala | $19 |
| GlaxoSmithKline | Meals · 2025-05-06 | Nucala | $6 |
| Insmed | Meals · 2025-04-22 | Arikayce | $31 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-04-16 | Ofev | $25 |
| Insmed | Meals · 2025-04-09 | Arikayce | $5 |
| GlaxoSmithKline | Meals · 2025-02-26 | Trelegy Ellipta | $7 |
| GlaxoSmithKline | Meals · 2025-01-21 | Trelegy Ellipta | $9 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $218
| GlaxoSmithKline | Trelegy Ellipta | $71 | 3 payments
|
| Shionogi | Fetroja | $34 | 1 payment
|
| Regeneron Healthcare Solutions | Dupixent | $26 | 1 payment
|
| Boehringer Ingelheim Pharmaceuticals | Ofev | $24 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Airsupra | $23 | 1 payment
|
| Insmed | Arikayce | $22 | 1 payment
|
| ANI Pharmaceuticals | Purified Cortrophin Gel | $20 | 1 payment
|
2023: $632
| GlaxoSmithKline | Trelegy Ellipta | $249 | 18 payments
|
| Mallinckrodt Hospital Products | Acthar | $118 | 2 payments
|
| AstraZeneca Pharmaceuticals LP | Fasenra | $84 | 6 payments
|
| Boehringer Ingelheim Pharmaceuticals | Ofev | $47 | 2 payments
|
| Actelion Pharmaceuticals US | Opsumit | $42 | 2 payments
|
| ANI Pharmaceuticals | Purified Cortrophin Gel | $24 | 1 payment
|
| Takeda Pharmaceuticals U.S.A. | Glassia | $20 | 1 payment
|
| Mylan Specialty L.P. | Yupelri | $17 | 1 payment
|
| Genentech USA | Xolair | $16 | 1 payment
|
| Genzyme | Dupixent | $14 | 1 payment
|
2022: $817
| GlaxoSmithKline | Trelegy Ellipta | $286 | 26 payments
|
| AstraZeneca Pharmaceuticals LP | Fasenra | $201 | 13 payments
|
| Boehringer Ingelheim Pharmaceuticals | Stiolto Respimat | $70 | 4 payments
|
| Regeneron Healthcare Solutions | Dupixent | $59 | 3 payments
|
| Mylan Specialty L.P. | Yupelri | $40 | 2 payments
|
| Genentech USA | Xolair | $39 | 3 payments
|
| Grifols USA | Prolastin-C Liquid | $36 | 2 payments
|
| Exeltis USA | Purified Cortrophin Gel | $34 | 2 payments
|
| Inogen | Inogenone | $22 | 2 payments
|
| Takeda Pharmaceuticals U.S.A. | Glassia | $16 | 1 payment
|
| Genzyme | Dupixent | $14 | 1 payment
|
2021: $748
| GlaxoSmithKline | Trelegy Ellipta | $221 | 24 payments
|
| Boehringer Ingelheim Pharmaceuticals | Ofev | $198 | 16 payments
|
| Takeda Pharmaceuticals U.S.A. | Glassia | $138 | 9 payments
|
| United Therapeutics | Orenitram | $44 | 2 payments
|
| Mallinckrodt Hospital Products | Acthar | $39 | 3 payments
|
| Bayer HealthCare Pharmaceuticals | Adempas | $30 | 2 payments
|
| Advanced Respiratory | The Vest System Model 105 Home Care | $29 | 2 payments
|
| Boston Scientific | Watchman | $18 | 1 payment
|
| Insmed | Arikayce | $17 | 1 payment
|
| Grifols USA | Prolastin-C Liquid | $14 | 1 payment
|
2020: $479
| GlaxoSmithKline | Nucala | $252 | 32 payments
|
| Boehringer Ingelheim Pharmaceuticals | Stiolto Respimat | $59 | 4 payments
|
| AstraZeneca Pharmaceuticals LP | Fasenra | $51 | 4 payments
|
| Mallinckrodt Hospital Products | Acthar | $37 | 3 payments
|
| Takeda Pharmaceuticals U.S.A. | Glassia | $30 | 2 payments
|
| Actelion Pharmaceuticals US | Opsumit | $18 | 1 payment
|
| Advanced Respiratory | The Vest System Model 105 Home Care | $18 | 1 payment
|
| Philips Electronics North America | (8874) Incourage | $15 | 1 payment
|
2019: $59
| Mallinckrodt Enterprises | Acthar | $22 | 1 payment
|
| Mylan Specialty L.P. | Yupelri | $20 | 1 payment
|
| CSL Behring | Zemaira | $17 | 1 payment
|
Professional record
- NPI
- 1922269604
- Licence
- AR E7721
- Gender
- Male
More record details
- Sole proprietor
- Yes
- Medicaid ID
- AR 199127001
- Taxonomy
- Federal specialty code 207RP1001X (207RP1001X)
- Mailing address
- 154a W Foothill Blvd # 281, Upland, CA, 91786
- NPI first listed
- 2008-06-24
- NPI last updated
- 2024-11-07
- NPI record certified
- 2024-11-07
This is when the NPI record was last certified, not a medical board exam.